"My only question is, who is our bigger enemy, Jay Powell or Chairman Xi?" Trump wrote amid a series of tweets that rattled markets Friday.Politicsread more
Stocks dropped after Donald Trump ordered that U.S. manufacturers find alternatives to their operations in China.US Marketsread more
"We don't need China and, frankly, would be far better off without them," Trump tweeted.Politicsread more
Yields slipped after Powell said that the central bank will continue to act as appropriate to sustain the economic expansion.Bondsread more
Here are the products that stand to be the most affected by China's new tariffs on $75 billion worth of U.S. goods.Marketsread more
The president tweeted Friday morning that he was ordering "our great American companies" to "immediately start looking for an alternative to China."Marketsread more
Multinationals that rely on the supply chain from China are tumbling after President Donald Trump ordered them to find alternatives to their Chinese operations.Marketsread more
Semiconductor stocks and shares of Apple slid on Friday after President Donald Trump said U.S. companies should "immediately start looking for an alternative" to their...Technologyread more
The two American car companies are among the top exporters of U.S.-produced vehicles to China along with BMW and Daimler/Mercedes-Benz, according to industry data obtained by...Autosread more
Powell repeats his pledge to keep the economic expansion going while acknowledging that tariffs and other factors are causing growth to slow.The Fedread more
These are the stocks posting the largest moves in midday trading.Market Insiderread more
Generic drug maker maker Mylan on Wednesday reported a first-quarter profit that edged past expectations, helped by demand for products it gained through the acquisition of Swedish drugmaker Meda.
Shares of the EpiPen maker rose 2.3 percent to $38.87 in early trading after Mylan also backed its full-year forecast.
Mylan's forecast for 2017 profit and revenue, which it first announced in March, was in sharp contrast to downbeat expectations from rivals despite prolonged pressure and scrutiny on pricing for generic drugs in the United States.
"Our overall expectations for the global pricing environment are unchanged and we are still predicting mid-single digit percentage erosion globally for the year," Mylan President Rajiv Malik said.
Mylan's affirmation of its 2017 forecast may be comforting to some following the U.S. Food and Drug Administration's (FDA) recent rejection of the company's generic version of GlaxoSmithKline's blockbuster Advair asthma treatment, Goldman Sachs analysts said.
So far, Mylan has provided no details of the FDA's concerns or how long the product might be delayed.
Mylan has come under fire for sharply increasing the price of EpiPen and classifying the life-saving treatment as a generic rather than a branded product, which led to much smaller rebates to state Medicaid programs.
The company said first-quarter sales of EpiPen in North America declined due to increased competition and the launch of its authorized generic.
In March, the company said it was recalling thousands of EpiPen devices following reports of the treatment failing to work in emergencies.
Mylan said net income surged to $66.4 million, or 12 cents per share in the first quarter ended March 31, from $13.9 million, or 3 cents per share, a year earlier.
Excluding one-time items, Mylan earned 93 cents per share, beating analysts' average estimate by 1 cent, according to Thomson Reuters I/B/E/S.
Revenue rose 24 percent to $2.72 billion. Analysts on average had expected $2.84 billion.